CTSO

Cytosorbents Corp (CTSO) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Cytosorbents Corporation is a medical device company focused on blood purification technologies for intensive care and cardiac surgery. Its lead product, CytoSorb, is approved in the EU and distributed globally, while its U.S. pipeline product, DrugSorb-ATR, remains under FDA review. The Company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Stability: Revenue remained flat year-over-year for both the quarter (+0.2%) and six-month period (+0.8%). Growth in distributor and strategic partner territories outside Germany was offset by a decline in German sales due to a reduced sales force.
• Operating Efficiency: Operating loss improved by 27% for the quarter and 24% for the six-month period compared to 2025. This was driven by a 13% reduction in SG&A expenses and improved gross margins.
• Foreign Currency Impact: The Company recorded a loss of $0.91 million on foreign currency transactions in Q2 2026, a significant reversal from a $6.18 million gain in Q2 2025, due to the weakening Euro against the U.S. dollar.
• Restructuring: The Company incurred $0.27 million in restructuring charges in Q2 2026 (totaling $0.31 million YTD) as part of a strategic workforce reduction plan that reduced headcount by approximately 23%.
• Debt Structure: Following an amendment in November 2025, the Company extended its interest-only period to December 31, 2026. However, $14.15 million of debt is now classified as current due to the approaching maturity and failure to meet the revenue milestone required for further extension.

Outlook, Risks, and Contingencies

• Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for the next 12 months. With only $4.4 million in unrestricted cash and a history of operating losses, the Company expects to achieve operating cash flow breakeven in the second half of 2026 but may require additional capital.
• Regulatory Status: The FDA denied the original DrugSorb-ATR application in August 2025. The Company plans to submit a new De Novo application in early 2027 after generating additional mechanistic data. Approval is now expected beyond the December 2026 deadline required to access Tranche 2b of its debt facility.
• Nasdaq Compliance: The Company is not in compliance with Nasdaq's Minimum Bid Price Requirement (deadline: Sept 28, 2026) and Market Value of Listed Securities (MVLS) Requirement (deadline: Dec 28, 2026). Failure to comply could result in delisting.
• Internal Controls: The Company disclosed material weaknesses in internal controls over financial reporting related to stock-based compensation accounting and financial statement consolidation. Remediation is ongoing.

Investor Verification Checklist

• Liquidity Runway: Verify if the Company can achieve operating cash flow breakeven in H2 2026 without raising additional capital, given the $14.15 million debt maturity in 2027.
• Debt Covenant Compliance: Monitor the ability to meet revenue and cash burn targets required to avoid default on the Avenue Capital Group loan.
• Regulatory Timeline: Confirm the status of the new DrugSorb-ATR De Novo submission and the likelihood of FDA approval by late 2027.
• Nasdaq Listing: Track stock price performance to ensure compliance with the $1.00 minimum bid price and $35 million MVLS requirements by their respective deadlines.
• Internal Control Remediation: Review future filings for confirmation that material weaknesses in financial reporting have been fully remediated.